Bioresorbable Vascular Scaffold Market Size, Share and Growth Outlook, 2026

Bioresorbable Vascular Scaffold Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Bioresorbable Vascular Scaffold Market size is forecast to increase from $567.06 Million in 2026 to $1977.63 Million in 2034 at a CAGR of 16.9% between 2026 and 2034.

The Bioresorbable Vascular Scaffold market report provides detailed analysis and outlook of Bioresorbable Vascular Scaffold segments including By Product (Drug-Eluting Bioresorbable Scaffolds, Bare Bioresorbable Scaffolds), By Material Type (Polymer-Based Scaffolds, Metallic-Based Scaffolds), By Application (Coronary Artery Interventions, Peripheral Artery Interventions), By End-User (Hospitals and Cardiac Centers, Ambulatory Surgical Centers, Specialty Clinics) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Bioresorbable Vascular Scaffold Industry Overview

Dissolving Scaffold Technologies Redefine Peripheral Artery Disease Treatment

The Bioresorbable Vascular Scaffold industry is gaining significant momentum as cardiovascular device manufacturers develop next-generation solutions that provide temporary vessel support while eliminating the long-term presence of permanent implants. These scaffolds are designed to restore blood flow, deliver therapeutic agents, and gradually dissolve after completing their clinical function, allowing the treated vessel to regain natural physiological behavior. A major advancement in the industry is Abbott’s receipt of CE Mark approval for the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System. Specifically developed for severe peripheral artery disease below the knee, the platform combines mechanical vessel support with localized everolimus drug delivery before fully resorbing within the body. Clinical data demonstrated that the scaffold reduced repeat procedures by 48% compared with conventional balloon angioplasty, highlighting the growing clinical value of bioresorbable technologies in peripheral vascular interventions. The increasing adoption of dissolving scaffold systems reflects a broader shift toward vessel restoration therapies that aim to improve long-term patient outcomes while minimizing permanent foreign material implantation.

Innovative Polymer Platforms Advance Clinical Performance

Material science innovation continues to play a central role in the evolution of the Bioresorbable Vascular Scaffold market. Manufacturers are investing heavily in proprietary bioresorbable polymers capable of delivering improved mechanical strength, controlled degradation, and enhanced clinical outcomes. REVA Medical reported positive findings from its MOTIV clinical trial evaluating the MOTIV Sirolimus-Eluting Bioresorbable Vascular Scaffold for infrapopliteal lesions. Built using the company’s proprietary Tyrocore™ bioresorbable polymer platform, the scaffold demonstrated clinical superiority and strong limb salvage outcomes among patients with critical limb-threatening ischemia. The success of advanced polymer technologies is helping address historical challenges associated with early-generation bioresorbable devices, including structural integrity and long-term performance. As developers continue refining scaffold architecture and polymer composition, the industry is moving toward more durable and predictable solutions capable of supporting complex peripheral vascular disease treatment.

Economic Evidence Strengthens Adoption Across Healthcare Systems

In addition to clinical benefits, healthcare providers and hospital systems are increasingly evaluating bioresorbable vascular scaffolds based on their economic impact. Long-term cost-effectiveness has emerged as a key factor supporting adoption of advanced vascular technologies, particularly in the management of chronic peripheral artery disease where repeat interventions can significantly increase healthcare expenditures. Data presented from the LIFE-BTK trial provided strong evidence supporting the economic value of bioresorbable vascular scaffolds. The analysis demonstrated a 93.2% probability that the Esprit BTK scaffold would be highly cost-effective over a two-year period due to its ability to substantially reduce target lesion revascularization procedures. By lowering the need for additional interventions and improving long-term vessel patency, bioresorbable scaffold technologies are becoming increasingly attractive to healthcare systems seeking both clinical effectiveness and economic efficiency. These findings are reinforcing the position of bioresorbable vascular scaffolds as a transformative technology within peripheral vascular disease management.

Bioresorbable Vascular Scaffold Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Bioresorbable Vascular Scaffold market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, Biotronik SE & Co. KG, Meril Life Sciences Pvt. Ltd., Elixir Medical Corporation, Lepu Medical Technology Co., Ltd., Shanghai MicroPort Medical (Group) Co., Ltd., REVA Medical, LLC, Lifetech Scientific Corporation, Arterial Remodeling Technologies (ART), Amaranth Medical, Inc.. The Bioresorbable Vascular Scaffold market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Bioresorbable Vascular Scaffold industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Bioresorbable Vascular Scaffold Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Bioresorbable Vascular Scaffold companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Bioresorbable Vascular Scaffold markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Bioresorbable Vascular Scaffold Market Competitive Benchmarking and Company Analysis

Leading companies in Bioresorbable Vascular Scaffold industry include- Abbott Laboratories, Biotronik SE & Co. KG, Meril Life Sciences Pvt. Ltd., Elixir Medical Corporation, Lepu Medical Technology Co., Ltd., Shanghai MicroPort Medical (Group) Co., Ltd., REVA Medical, LLC, Lifetech Scientific Corporation, Arterial Remodeling Technologies (ART), Amaranth Medical, Inc.. The Bioresorbable Vascular Scaffold market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Bioresorbable Vascular Scaffold Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Bioresorbable Vascular Scaffold market remains one of the strongest-performing segments in the country.
The US Bioresorbable Vascular Scaffold Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Bioresorbable Vascular Scaffold market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Bioresorbable Vascular Scaffold industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Bioresorbable Vascular Scaffold markets

Canada's strong Bioresorbable Vascular Scaffold sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Bioresorbable Vascular Scaffold market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Bioresorbable Vascular Scaffold Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Bioresorbable Vascular Scaffold market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Bioresorbable Vascular Scaffold population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Bioresorbable Vascular Scaffold industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Bioresorbable Vascular Scaffold market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Bioresorbable Vascular Scaffold sales through 2034

France Bioresorbable Vascular Scaffold companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Bioresorbable Vascular Scaffold Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Bioresorbable Vascular Scaffold distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Bioresorbable Vascular Scaffold Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Bioresorbable Vascular Scaffold market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Bioresorbable Vascular Scaffold industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Bioresorbable Vascular Scaffold industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Bioresorbable Vascular Scaffold Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Bioresorbable Vascular Scaffold market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Bioresorbable Vascular Scaffold market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Bioresorbable Vascular Scaffold Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Bioresorbable Vascular Scaffold Market Segmentation

By Product
Drug-Eluting Bioresorbable Scaffolds
Bare Bioresorbable Scaffolds
By Material Type
Polymer-Based Scaffolds
Metallic-Based Scaffolds
By Application
Coronary Artery Interventions
Peripheral Artery Interventions
By End-User
Hospitals and Cardiac Centers
Ambulatory Surgical Centers
Specialty Clinics

Top Companies in Bioresorbable Vascular Scaffold Industry

Abbott Laboratories
Biotronik SE & Co. KG
Meril Life Sciences Pvt. Ltd.
Elixir Medical Corporation
Lepu Medical Technology Co., Ltd.
Shanghai MicroPort Medical (Group) Co., Ltd.
REVA Medical, LLC
Lifetech Scientific Corporation
Arterial Remodeling Technologies (ART)
Amaranth Medical, Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025